Sonnet Historical Cash Flow

SONN Stock  USD 2.41  0.20  7.66%   
Analysis of Sonnet Biotherapeutics cash flow over time is an excellent tool to project Sonnet Biotherapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 5.1 K or Other Cashflows From Financing Activities of 2.1 M as it is a great indicator of Sonnet Biotherapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Sonnet Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sonnet Biotherapeutics is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Sonnet Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Sonnet balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sonnet's non-liquid assets can be easily converted into cash.

Sonnet Biotherapeutics Cash Flow Chart

At this time, Sonnet Biotherapeutics' Total Cashflows From Investing Activities is very stable compared to the past year. As of the 3rd of December 2024, Cash Flows Other Operating is likely to grow to about 2 M, while Sale Purchase Of Stock is likely to drop about 167.2 K.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.
Most accounts from Sonnet Biotherapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Sonnet Biotherapeutics' Total Cashflows From Investing Activities is very stable compared to the past year. As of the 3rd of December 2024, Cash Flows Other Operating is likely to grow to about 2 M, while Sale Purchase Of Stock is likely to drop about 167.2 K.

Sonnet Biotherapeutics cash flow statement Correlations

-0.330.050.010.05-0.10.280.1-0.88-0.19-0.030.44-0.580.07-0.220.85-0.850.160.290.060.38-0.060.07
-0.33-0.020.07-0.75-0.010.470.120.190.03-0.030.210.940.1-0.49-0.160.13-0.31-0.42-0.260.09-0.130.13
0.05-0.020.210.08-0.610.06-0.12-0.030.180.590.49-0.020.10.00.04-0.04-0.010.250.06-0.020.00.68
0.010.070.210.15-0.810.550.280.180.96-0.570.410.140.440.19-0.15-0.04-0.13-0.17-0.640.560.33-0.17
0.05-0.750.080.15-0.03-0.33-0.380.180.140.06-0.06-0.66-0.270.280.090.120.190.430.37-0.20.06-0.17
-0.1-0.01-0.61-0.81-0.03-0.45-0.22-0.06-0.80.27-0.54-0.05-0.3-0.10.020.1-0.120.110.46-0.34-0.52-0.12
0.280.470.060.55-0.33-0.450.63-0.060.4-0.390.780.33-0.06-0.610.41-0.190.18-0.25-0.250.30.31-0.3
0.10.12-0.120.28-0.38-0.220.630.020.29-0.370.280.12-0.01-0.140.07-0.060.32-0.14-0.20.090.38-0.47
-0.880.19-0.030.180.18-0.06-0.060.020.33-0.1-0.220.4-0.310.07-0.620.87-0.02-0.140.08-0.410.22-0.22
-0.190.030.180.960.14-0.80.40.290.33-0.60.220.180.440.34-0.360.11-0.04-0.28-0.640.410.48-0.25
-0.03-0.030.59-0.570.060.27-0.39-0.37-0.1-0.60.05-0.07-0.19-0.10.070.05-0.130.420.54-0.37-0.540.7
0.440.210.490.41-0.06-0.540.780.28-0.220.220.050.03-0.19-0.660.61-0.170.20.09-0.060.270.180.13
-0.580.94-0.020.14-0.66-0.050.330.120.40.18-0.070.030.18-0.26-0.460.32-0.3-0.52-0.340.01-0.040.05
0.070.10.10.44-0.27-0.3-0.06-0.01-0.310.44-0.19-0.190.180.64-0.42-0.35-0.61-0.21-0.790.72-0.270.3
-0.22-0.490.00.190.28-0.1-0.61-0.140.070.34-0.1-0.66-0.260.64-0.650.0-0.30.03-0.350.19-0.080.08
0.85-0.160.04-0.150.090.020.410.07-0.62-0.360.070.61-0.46-0.42-0.65-0.580.350.320.380.060.02-0.02
-0.850.13-0.04-0.040.120.1-0.19-0.060.870.110.05-0.170.32-0.350.0-0.58-0.04-0.090.03-0.320.09-0.09
0.16-0.31-0.01-0.130.19-0.120.180.32-0.02-0.04-0.130.2-0.3-0.61-0.30.35-0.04-0.160.45-0.580.79-0.56
0.29-0.420.25-0.170.430.11-0.25-0.14-0.14-0.280.420.09-0.52-0.210.030.32-0.09-0.160.350.03-0.410.4
0.06-0.260.06-0.640.370.46-0.25-0.20.08-0.640.54-0.06-0.34-0.79-0.350.380.030.450.35-0.82-0.04-0.04
0.380.09-0.020.56-0.2-0.340.30.09-0.410.41-0.370.270.010.720.190.06-0.32-0.580.03-0.82-0.280.22
-0.06-0.130.00.330.06-0.520.310.380.220.48-0.540.18-0.04-0.27-0.080.020.090.79-0.41-0.04-0.28-0.58
0.070.130.68-0.17-0.17-0.12-0.3-0.47-0.22-0.250.70.130.050.30.08-0.02-0.09-0.560.4-0.040.22-0.58
Click cells to compare fundamentals

Sonnet Biotherapeutics Account Relationship Matchups

Sonnet Biotherapeutics cash flow statement Accounts

201920202021202220232024 (projected)
Begin Period Cash Flow438.5K5.4K7.3M27.6M3.1M5.1K
Capital Expenditures1.7M2.4M3.6K896.5K443.3K2.5M
Total Cash From Operating Activities(1.1M)(2.2M)(22.6M)(27.7M)(21.3M)(2.3M)
End Period Cash Flow524.1K35.7K27.6M3.1M2.3M33.9K
Net Borrowings303.3K(355.2K)(526.1K)(20.4K)(473.5K)(449.8K)
Total Cashflows From Investing Activities(2.4M)678.7K(3.6K)(896.5K)780.5K819.5K
Change To Netincome1.5M8.6M1.3M1.8M9.9M10.4M
Change To Liabilities2.6M155.9K1.7M621.1K179.3K170.3K

Pair Trading with Sonnet Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sonnet Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sonnet Stock

  0.81ME 23Andme HoldingPairCorr
  0.79VALN Valneva SE ADRPairCorr

Moving against Sonnet Stock

  0.76VCYT VeracytePairCorr
  0.76SABSW SAB BiotherapeuticsPairCorr
  0.7VERA Vera TherapeuticsPairCorr
  0.65VCEL Vericel Corp OrdPairCorr
  0.64DRUG Bright Minds BiosciencesPairCorr
The ability to find closely correlated positions to Sonnet Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sonnet Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sonnet Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sonnet Biotherapeutics Holdings to buy it.
The correlation of Sonnet Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sonnet Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sonnet Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sonnet Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.96)
Revenue Per Share
0.019
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.97)
Return On Equity
(2.65)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.